You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Unadjusted risk of inpatient mortality, length of stay in hospital, and healthcare expenditures for chemotherapy- induced neutropenic complications requiring inpatient care, by duration of filgrastim prophylaxis

From: Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis

  Days of Filgrastim Prophylaxis
  1-3 4-6 > = 7
Mortality, % (95% CI) 8.4 (4.6-14.8) 4.0 (1.4-11.1) 0.0 (0.0-10.2)
  (n = 119) (n = 75) (n = 34)
LOS (days), mean (95% CI) 7.4 (6.4-8.3) 7.1 (5.7-8.5) 6.5 (4.9-8.0)
  (n = 243) (n = 99) (n = 40)
Expenditures, mean (95% CI)
 Inpatient $18,509 (14,195-23,145) $14,527 (10,758-19,243) $12,544 (9,063-16,315)
 Outpatient $226 (126–350) $356 (148–630) $581 (145–1,180)
 Pharmacy $177 (68–329) $24 (13–39) $41 (10–88)
 Total $18,912 (14,570-23,581) $14,907 (11,155-19,728) $13,165 (9,595-17,144)
  (n = 225) (n = 94) (n = 39)
  1. *n’s indicate the number of patient-cycles considered in analyses of study measures; among patients who developed CINC (n = 382), those with missing data on study measures- because such data were not recorded on claims or were not provided by some health plans- were excluded from corresponding analyses.
  2. **Only patients with paid amounts > $0 were considered in these analyses.